Clinical Trial Update: Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating apatinib combined with oral etoposide in metastatic HER2-negative breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Apatinib (apatinib)
• Etoposide (Etoposide)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED